4.6 Article

Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma

期刊

CELLS
卷 10, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/cells10123378

关键词

immunology; tumor infiltrating lymphocytes; multiplex immunofluorescence histology; glioblastoma; human

资金

  1. University of Virginia Cancer Center Schiff Foundation
  2. University of Virginia Cancer Center Support Grant [NIH P30 CA044579]
  3. Willowcroft Foundation
  4. NIH/NCI [K25CA181638]

向作者/读者索取更多资源

This study revealed that proliferating CD8 T cell density and higher CD8/CD4 ratios are independent predictors of overall survival in patients with GBM. Contrarily, higher mean intensities of IFN gamma in the tumors were associated with shorter overall survival, suggesting the importance of promoting tumor-reactive CD8(+) T cells and interfering with the immunoregulatory effects of IFN gamma in the tumor microenvironment for enhanced survival.
Background: tumor-infiltrating lymphocytes are prognostic in many human cancers. However, the prognostic value of lymphocytes infiltrating glioblastoma (GBM), and roles in tumor control or progression are unclear. We hypothesized that B and T cell density, and markers of their activity, proliferation, differentiation, or function, would have favorable prognostic significance for patients with GBM. Methods: initial resection specimens from 77 patients with IDH1/2 wild type GBM who received standard-of-care treatment were evaluated with multiplex immunofluorescence histology (mIFH), for the distribution, density, differentiation, and proliferation of T cells and B cells, as well as for the presence of tertiary lymphoid structures (TLS), and IFN gamma expression. Immune infiltrates were evaluated for associations with overall survival (OS) by univariate and multivariate Cox proportional hazards modeling. Results: in univariate analyses, improved OS was associated with high densities of proliferating (Ki67(+)) CD8(+) cells (HR 0.36, p = 0.001) and CD20(+) cells (HR 0.51, p = 0.008), as well as CD8(+)Tbet(+) cells (HR 0.46, p = 0.004), and ROR gamma t(+) cells (HR 0.56, p = 0.04). Conversely, IFN gamma intensity was associated with diminished OS (HR 0.59, p = 0.036). In multivariable analyses, adjusting for clinical variables, including age, resection extent, Karnofsky Performance Status (KPS), and MGMT methylation status, improved OS was associated with high densities of proliferating (Ki67(+)) CD8(+) cells (HR 0.15, p < 0.001), and higher ratios of CD8(+) cells to CD4(+) cells (HR 0.31, p = 0.005). Diminished OS was associated with increases in patient age (HR 1.21, p = 0.005) and higher mean intensities of IFN gamma (HR 2.13, p = 0.027). Conclusions: intratumoral densities of proliferating CD8 T cells and higher CD8/CD4 ratios are independent predictors of OS in patients with GBM. Paradoxically, higher mean intensities of IFN gamma in the tumors were associated with shorter OS. These findings suggest that survival may be enhanced by increasing proliferation of tumor-reactive CD8(+) T cells and that approaches may be needed to promote CD8(+) T cell dominance in GBM, and to interfere with the immunoregulatory effects of IFN gamma in the tumor microenvironment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype

Maria Diaz, Jasmin Jo, Mark Smolkin, Sarah Jane Ratcliffe, David Schiff

Summary: The study found that patients with lower-grade gliomas have a higher VTE risk, which is decreased in the presence of an IDH mutation. The incidence of VTE in glioblastoma patients is not affected by MGMT promoter methylation status.

NEUROLOGY (2021)

Article Oncology

Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?

Jasmin Jo, Joseph Donahue, Guneet Sarai, Gina Petroni, David Schiff

Summary: This study aimed to assess the risk of intracranial hemorrhage (ICH) in high-grade glioma (HGG) patients with venous thromboembolism (VTE) on low molecular weight heparin (LMWH). The retrospective matched cohort study found that therapeutic LMWH is not associated with a substantially increased risk of ICH in HGG patients, and the median survival was similar among all three cohorts.

NEURO-ONCOLOGY (2022)

Review Oncology

Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients

Maria Diaz, Jasmin Jo

Summary: Brain tumor patients have a higher risk of VTE, and recent studies have identified new risk factors and molecular mechanisms associated with VTE in these patients. Anticoagulation is necessary for VTE treatment in brain tumor patients, and DOACs may be a feasible option.

CURRENT ONCOLOGY REPORTS (2022)

Review Oncology

Current Considerations in the Treatment of Grade 3 Gliomas

Jasmin Jo, David Schiff

Summary: Treatment recommendations for grade 3 gliomas depend on their histopathologic and molecular phenotype. The current treatments involve surgery, radiation therapy, and chemotherapy. The addition of temozolomide after radiation therapy improves outcomes for non-codeleted grade 3 IDH mutant astrocytoma. For codeleted oligodendroglioma, the recommended treatment includes procarbazine, CCNU, and vincristine regimen. Novel agents targeting IDH mutation and its metabolic effects are being investigated to further improve patient outcomes.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Article Clinical Neurology

Predictors of early, recurrent, and intractable seizures in low-grade glioma

Jasmin Jo, Kathryn Nevel, Ryan Sutyla, Mark Smolkin, M. Beatriz Lopes, David Schiff

Summary: Seizures are common among patients with low-grade glioma (LGG), with no significant differences in preoperative or postoperative seizure rates by WHO 2016 classification. Male patients have a higher seizure incidence and are more likely to develop intractable seizures both preoperatively and postoperatively. The study also found a trend towards higher seizure incidence preoperatively in LGG patients with IDH mutation.

NEURO-ONCOLOGY PRACTICE (2021)

暂无数据